Antenatal exposure to betamethasone induces placental 11β-hydroxysteroid dehydrogenase type 2 expression and the adult metabolic disorders in mice

PLoS One. 2018 Sep 13;13(9):e0203802. doi: 10.1371/journal.pone.0203802. eCollection 2018.

Abstract

Antenatal overexposure to glucocorticoids causes fetal intrauterine growth restriction (IUGR) and adult metabolic disorders. 11β-hydroxysteroid dehydrogenase (11β-HSD) 1 and 2 are key enzymes for glucocorticoid metabolism, however, the detailed effects of antenatal overexposure to glucocorticoids on placental 11β-HSD1 and 2 expression and adult metabolic disorders remain obscure. Here, we report that, in placenta 11β-HSD1 is diffusely localized, whereas 11β-HSD2 is specifically expressed in labyrinthine layer. Exposure of pregnant dams to betamethasone significantly increases the expression of placental 11β-HSD2 but not 11β-HSD1, and decreases the weights of fetuses but not placentas. Antenatal exposure to betamethasone leads to either significant weight loss in the offspring younger than 10-week-old, or weight gain in those older than 14-week-old. Furthermore, antenatal exposure to betamethasone results in coexistence of various metabolic disorders in adult offspring, including hyperglycemia, glucose intolerance, low insulin secretory capacity and hyperlipidemia. The present study demonstrates that exposure of pregnant dams to betamethasone induces the expression of placental 11β-HSD2 but not 11β-HSD1, leads to fetal IUGR and causes adult metabolic disorders, providing evidence for fetal origins of adult diseases and the potential role of placental 11β-HSD2 in them.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 11-beta-Hydroxysteroid Dehydrogenase Type 1 / metabolism
  • 11-beta-Hydroxysteroid Dehydrogenase Type 2 / metabolism*
  • Animals
  • Betamethasone / adverse effects*
  • Corticosterone / blood
  • Dose-Response Relationship, Drug
  • Female
  • Fetal Growth Retardation / chemically induced
  • Fetal Growth Retardation / enzymology
  • Glucocorticoids / adverse effects*
  • Glucose / metabolism
  • Insulin / metabolism
  • Lipids / blood
  • Male
  • Metabolic Diseases / chemically induced
  • Metabolic Diseases / enzymology
  • Mice, Inbred ICR
  • Placenta / drug effects*
  • Placenta / enzymology*
  • Placenta / physiology
  • Pregnancy
  • Prenatal Exposure Delayed Effects*

Substances

  • Glucocorticoids
  • Insulin
  • Lipids
  • Betamethasone
  • 11-beta-Hydroxysteroid Dehydrogenase Type 1
  • 11-beta-Hydroxysteroid Dehydrogenase Type 2
  • Glucose
  • Corticosterone

Grants and funding

This work was supported by 973 Program (No. 2011CB944403), National Natural Science Foundation of China (No.81170787, No.31071292, No.30973580), Natural Science Foundation of Zhejiang Province, China (No. R2110269), and Qianjiang Talent Program, Zhejiang Province, China (No. 2011R10018) (to X. W.), and National Natural Science Foundation of China (No.81601308) (to Y. P.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.